Conversely, a significant increase (p < 0.005 vs. CRC or GC patients with T1 stage) in the expression levels of both the ERK1/2 and p-ERK1/2 proteins, evaluated by immunofluorescence analysis, was demonstrated in the CRC pathological tissues at the highest investigated TNM stage, namely, T4 (Figures 5A, B). The gene discussed is MAPK3; the disease is gastric cancer.